| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.31 | 2e-06 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.26 | 1e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.25 | 6e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.22 | 0.0001 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.18 | 0.0007 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.001 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |